HAVCR2 and myelodysplastic syndrome: MBG453, a high-affinity humanized anti-TIM-3 IgG4 antibody, blocks TIM-3 function and is currently being evaluated in clinical trials of patients with high-risk MDS and AML (Table 1) (Borate et al., 2019; Zeidan et al., 2019).